CA2773611A1 - Utilisation de guaifenesine pour inhiber la secretion de mucine - Google Patents

Utilisation de guaifenesine pour inhiber la secretion de mucine Download PDF

Info

Publication number
CA2773611A1
CA2773611A1 CA2773611A CA2773611A CA2773611A1 CA 2773611 A1 CA2773611 A1 CA 2773611A1 CA 2773611 A CA2773611 A CA 2773611A CA 2773611 A CA2773611 A CA 2773611A CA 2773611 A1 CA2773611 A1 CA 2773611A1
Authority
CA
Canada
Prior art keywords
composition
guaifenesin
administering
effective amount
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2773611A
Other languages
English (en)
Inventor
Helmut Albrecht
K. Chul Kim
Jeanclare Seagrave
Bruce K. Rubin
Gail Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RB Health US LLC
Original Assignee
Reckitt Benckiser LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,517 external-priority patent/US20110065744A1/en
Priority claimed from GBGB1002039.4A external-priority patent/GB201002039D0/en
Application filed by Reckitt Benckiser LLC filed Critical Reckitt Benckiser LLC
Publication of CA2773611A1 publication Critical patent/CA2773611A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2773611A 2009-09-12 2010-09-13 Utilisation de guaifenesine pour inhiber la secretion de mucine Abandoned CA2773611A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/558,517 US20110065744A1 (en) 2009-09-12 2009-09-12 Method Of Inhibiting Mucin Secretion
US12/558,517 2009-09-12
GB1002039.4 2010-02-09
GBGB1002039.4A GB201002039D0 (en) 2010-02-09 2010-02-09 Method of inhibiting mucin secretion
PCT/GB2010/051525 WO2011030163A1 (fr) 2009-09-12 2010-09-13 Utilisation de guaifénésine pour inhiber la sécrétion de mucine

Publications (1)

Publication Number Publication Date
CA2773611A1 true CA2773611A1 (fr) 2011-03-17

Family

ID=42941393

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2773611A Abandoned CA2773611A1 (fr) 2009-09-12 2010-09-13 Utilisation de guaifenesine pour inhiber la secretion de mucine

Country Status (12)

Country Link
EP (1) EP2475360A1 (fr)
JP (1) JP2013504554A (fr)
KR (1) KR20120068889A (fr)
CN (1) CN102596189A (fr)
AU (1) AU2010294008B2 (fr)
BR (1) BR112012005517A2 (fr)
CA (1) CA2773611A1 (fr)
MX (1) MX2012003042A (fr)
MY (1) MY161187A (fr)
RU (1) RU2012114323A (fr)
WO (1) WO2011030163A1 (fr)
ZA (1) ZA201201822B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065539A1 (en) * 2012-04-06 2015-03-05 The Uab Research Foundation Methods for Increasing CFTR Activity
KR102211605B1 (ko) * 2018-02-26 2021-02-04 대한민국 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
AU2003208967A1 (en) * 2002-02-04 2003-09-02 Pharmacia Corporation A combination for treating cold and cough
US20050249675A1 (en) * 2003-06-19 2005-11-10 Hsiao-Ling Hung Mucin synthesis inhibitors
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20080014261A1 (en) * 2006-07-12 2008-01-17 Giordano John A Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin

Also Published As

Publication number Publication date
BR112012005517A2 (pt) 2016-04-19
MY161187A (en) 2017-04-14
MX2012003042A (es) 2012-05-29
EP2475360A1 (fr) 2012-07-18
CN102596189A (zh) 2012-07-18
RU2012114323A (ru) 2013-10-20
ZA201201822B (en) 2013-05-29
JP2013504554A (ja) 2013-02-07
KR20120068889A (ko) 2012-06-27
AU2010294008A1 (en) 2012-04-05
AU2010294008B2 (en) 2014-08-14
WO2011030163A1 (fr) 2011-03-17

Similar Documents

Publication Publication Date Title
Caldwell et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis
US20120322719A1 (en) Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
Wen et al. Denatonium inhibits growth and induces apoptosis of airway epithelial cells through mitochondrial signaling pathways
CA2773611A1 (fr) Utilisation de guaifenesine pour inhiber la secretion de mucine
Malo et al. The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis
Ara et al. Correlation of habits and clinical findings with histopathological diagnosis in oral submucosal fibrosis patients
TW201609111A (zh) 人參皂苷ｍ１用於抑制腎纖維化之用途
Shih et al. Effect ofAnoectochilus formosanuson fibrosis and regeneration of the liver in rats.
Wu et al. Paeoniflorin confers ferroptosis resistance by regulating the gut microbiota and its metabolites in diabetic cardiomyopathy
Namba et al. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes
Herrmann et al. Type III collagen aminopropeptide and laminin PI levels in serum of patients with silicosis‐associated and idiopathic systemic scleroderma
Mattoli et al. Nedocromil sodium prevents the release of 15-hydroxyeicosatetraenoic acid from human bronchial epithelial cells exposed to toluene diisocyanate in vitro
US20110065744A1 (en) Method Of Inhibiting Mucin Secretion
Asifali et al. Frequency and clinical presentation of oral submucous fibrosis
Dobrek et al. Urinary kidney injury molecule-1 (KIM-1) excretion in rats with experimental cystitis induced by oxazaphosphorines
CN109021054A (zh) 一种fxr激动剂
Abdul Aziz Shaikh et al. Evaluation of salivary tumor necrosis factor α as a diagnostic biomarker in oral submucosal fibrosis and squamous cell carcinoma of the oral cavity and oropharynx: a cross sectional observational study
US20240295566A1 (en) Method for diagnosing and treating metabolic disorders
Lai et al. Substrate stiffness regulates the proliferation and inflammation of chondrocytes and macrophages through exosomes
US20240307361A1 (en) Method for diagnosing and treating irritable bowel syndrome
Maritzen et al. ClC-5 does not affect megalin expression and function in the thyroid
Hisamatsu et al. Effect of leukotriene C4 exposure on ciliated cells of the nasal mucosa
KR102617037B1 (ko) 폐암 재발 예측방법 및 재발 억제용 약학적 조성물
Bojan et al. A study to determine the association between tobacco smoking habit and oral candidal infection in median rhomboid glossitis by cytologic and histopathologic methods
Sharma et al. Gouty tophi-diagnosis clinched on cytology with review of literature

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150820

FZDE Discontinued

Effective date: 20190514